Pasithea Therapeutics (KTTA) Cost of Revenue (2022)
Pasithea Therapeutics recorded quarterly Cost of Revenue of -$1308.0 in Q4 2022, down 101.51% quarter-over-quarter from $86465.0 in Q3 2022.
Pasithea Therapeutics' Cost of Revenue history runs 1 years deep, the most recent figure standing at -$1308.0 for Q4 2022.
- In Q4 2022, Cost of Revenue changed N/A year-over-year to -$1308.0; the TTM figure through Dec 2022 stood at $113195.0 (changed N/A YoY), while the FY2022 annual figure was $113195.0, up 555.25% from the prior year.
- Cost of Revenue came in at -$1308.0 for Q4 2022 at Pasithea Therapeutics, down from $86465.0 in the prior quarter.
- In the past five years, Cost of Revenue ranged from a high of $86465.0 in Q3 2022 to a low of -$1308.0 in Q4 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 64.20 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 392.80 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 296.00 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 207.52 Mn |
| 10 | Pasithea Therapeutics | 17.41 Mn | 17.41 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | -1,308.00 |
| Dec 31, 2022 | -1,308.00 |
| Sep 30, 2022 | 86,465.00 |
| Sep 30, 2022 | 86,465.00 |
| Jun 30, 2022 | 15,101.00 |
| Jun 30, 2022 | 15,101.00 |
| Mar 31, 2022 | 12,937.00 |
| Mar 31, 2022 | 12,937.00 |